New weapon tested in fight against advanced cancers
NCT ID NCT05117476
Summary
This is an early-stage study testing the safety and initial effectiveness of a new drug called CLN-619. It is being given to adults with advanced solid tumors that have spread or cannot be removed by surgery. Researchers are testing CLN-619 by itself and combined with other approved cancer therapies to see how well patients tolerate it and if it helps control their cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Alfred Health
Melbourne, Victoria, 3004, Australia
-
Biokinetica
Józefów, 05-410, Poland
-
Carolina BioOncology Institute
Huntersville, North Carolina, 28078, United States
-
City of Hope
Duarte, California, 91010, United States
-
City of Hope
Irvine, California, 92618, United States
-
Clinica Universidad de Navarra
Pamplona, 31008, Spain
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Florida Cancer Specialists
Sarasota, Florida, 34232, United States
-
Hackensack Meridian Health
Hackensack, New Jersey, 07601, United States
-
Hospital Clinic Barcelona
Barcelona, 08036, Spain
-
Hospital Universitari Parc Tauli
Sabadell, 08208, Spain
-
Hospital Universitario Insular de Gran Canaria
Las Palmas de Gran Canaria, Gran Canaria, 35016, Spain
-
Linear Clinical Research
Nedlands, Western Australia, 6009, Australia
-
Med-Polonia Sp. zo. o.
Poznan, 60-693, Poland
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Monash Health
Clayton, Victoria, 3168, Australia
-
Narodowy Insytut Onkologii im Marii Sklodowskiej-Curie
Warsaw, 02-781, Poland
-
START Barcelona
Barcelona, 08023, Spain
-
START Madrid FJD
Madrid, 28040, Spain
-
START Midwest
Grand Rapids, Michigan, 49546, United States
-
START San Antonio
San Antonio, Texas, 78229, United States
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, 35233, United States
-
Virginia Cancer Center
Fairfax, Virginia, 22031, United States
Conditions
Explore the condition pages connected to this study.